To validate this mechanism, we treated HCC cells with recombinant CCN2 in a dose-dependent manner (0–2000 ng/m) and found that the p-Erk and Id-1 expression levels were significantly increased (Fig. 5c). This evidence concerns the gene CCN2 and hepatocellular carcinoma.